News | January 27, 2023
Torrent Pharmaceuticals posts Q3FY23 consolidated PAT at Rs. 283 Cr
The company has reported total income of Rs. 2481 crores during the period ended December 31, 2022
The company has reported total income of Rs. 2481 crores during the period ended December 31, 2022
Cell sorting technology supports researchers advancing new therapies
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
Granules now have a total of 53 ANDA approvals from USFDA
Medical Tourism will boost India’s economy
Asthma patients are more likely to have an asthma attack during winter
USFDA issued issued Form 483 with nine observations, which will be addressed within stipulated time.
It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV
The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) Ltd. located at Gifford House, Slaidburn Crescent, Southport, UK
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
Subscribe To Our Newsletter & Stay Updated
